Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entrectinib - Roche

Drug Profile

Entrectinib - Roche

Alternative Names: Entrectinib - Ignyta; NMS-E628; RG 6268; Rozlytrek; RXDX-101; TrkA/TrkB/TrkC/ROS1/ALK inhibitor - Roche

Latest Information Update: 07 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Alliance for Clinical Trials in Oncology; Chugai Biopharmaceuticals; Genentech; National Cancer Institute (USA); Roche; University of California at San Francisco
  • Class Antineoplastics; Benzamides; Indazoles; Piperazines; Pyrans; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Colorectal cancer; Solid tumours; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Solid tumours
  • Phase II Brain metastases; Malignant melanoma
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 19 Sep 2020 Updated efficacy and adverse events data from the phase I and II ALKA, STARTRK-1 and STARTRK-2 trials in Solid tumours presented at the 45th European Society for Medical Oncology Congress (ESMO-2020)
  • 19 Aug 2020 Roche completes the phase I STARTRK-1 trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Spain, South Korea and United Kingdom (PO) (NCT02097810) (EudraCT2014-001326-15)
  • 03 Aug 2020 Registered for Non-small cell lung cancer (Late-stage disease, Metastatic disease) in Hong Kong, Taiwan, New Zealand, South Korea (PO), Israel (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top